Epidermal growth factor receptor (994-1002) acetyl/amide
EGF-family receptor
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
1mg￥375.00300.00- +
-
5mg￥1050.00840.00- +
-
10mg￥1725.001380.00- +
-
25mg￥2462.001970.00- +
- 货号: ajcp4688
- CAS: N/A
- 别名: Ac-Asp-Ser-Asn-Phe-Tyr-Arg-Ala-Leu-Met-amide
- 分子式: C51H76N14O15S
- 分子量: 1157.3
- 纯度: ＞98%
- 溶解度: ≥115.7mg/mL in DMSO
- 储存: Store at -20°C
- 库存: 现货
Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 inhumans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands1. EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor ∥ (TGF∥). Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforme2. In this latter case a more or less specific mutation of EGFR, called EGFRvIII is often observed. Mutations, amplifications or misregulations of EGFR or family members are implicated in about 30% of all epithelial cancers. Mutations involving EGFR could lead to its constant activation, which could result in uncontrolled cell division - a predisposition for cancer. Consequently, mutations of EGFR have been identified in several types of cancer, and it is the target of an expanding class of anticancer therapies3.
参考文献:
1. Herbst RS (2004). "Review of epidermal growth factor receptor biology". Int. J. Radiat. Oncol. Biol. Phys. 59 (2 Suppl): 21-6.
2. Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, H?nin D, Lehy T, Aparicio T (November 2009). "Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus". Hum. Pathol. 40 (11): 1517-27.
3. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI (August 2007). "ErbB receptors: from oncogenes to targeted cancer therapies". J. Clin. Invest. 117 (8): 2051-8.
